Navigation Links
OctreoPharm Sciences GmbH Granted Global and Exclusive License for Oncology Diagnostic Product
Date:10/6/2011

BERLIN, October 6, 2011 /PRNewswire/ --

OctreoPharm Sciences GmbH, a Berlin-based specialist in nuclear medical pharmaceuticals (radiopharmaceuticals), announced today that it has received the worldwide exclusive license for the development and commercialization of SOMscan™, from Novartis Pharma AG.

The new Gallium-68-labeled radioactive contrast agent for positron emission tomography (PET) used by SOMscan has the potential to selectively detect and monitor neuroendocrine tumors. Following its potentialregistration, it could be, amongst other applications, used for this indication in conjunction with a new therapeutic drug.

SOMscan binds to four out of five specific receptor subtypes for the naturally-occurring hormone, somatostatin, on the cell surface of neuroendocrine tumors and uses high-resolution combined positron emission tomography and computed tomography (PET/CT) technique. This may allow detection of neuroendocrine tumors and metastases which previously escaped discovery in imaging diagnoses.  The only agent registered to date for the diagnosis of these tumors binds to only one of these receptor subtypes and uses the less sensitive gamma camera technique.

By leveraging high-resolution PET/CT imaging technique, the diagnosis of neuroendocrine tumors with SOMscan has the potential to be faster, more accurate, more reliable and more specific - with a marked reduction of radiation exposure for the patient. The expectation is that tumors and metastases down to a size of approximately four millimeters can be detected in accurate anatomical correlation with SOMscan. Since both the SOMscan diagnostic and therapeutic agent bind to the same tumor receptors, this makes individual monitoring and management of the course of the disease possible - another step towards personalized medicine… [http://www.octreopharmsciences.com/images/pdf/20111005_ops_pressrelease.pdf].

Contact:
Udo Blaseg
OctreoPharm Sciences GmbH
Campus Berlin-Buch
Robert-Rössle-Straße 10
13125 Berlin
Phone:  +49(0)30-9489-3360
eMail:  udo.blaseg@octreopharm.com



'/>"/>
SOURCE OctreoPharm
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Inovio Pharmaceuticals Leadership for Life Sciences Recognized in the Philadelphia Region
2. SV Life Sciences Appoints Veteran Diagnostics Professional Dr. Heiner Dreismann as Venture Partner
3. Particle Sciences Granted Patent on Self Sterilizing Medical Devices
4. Neurocrine Biosciences Receives Second Milestone Payment of $20 Million Under Abbott Collaboration Agreement
5. Coronado Biosciences Appoints Noah D. Beerman as Executive Vice President and Chief Operating Officer
6. ViroPharma Licenses Rights From Intellect Neurosciences for Product Candidate for Friedreichs Ataxia
7. Regado Biosciences, Inc. to Present at the Sofinnova Japan Biopharma Partnering Conference in Tokyo, Japan
8. BD Biosciences Introduces New Device Designed to Increase Cell Growth and Cell Culture Productivity
9. Neurocrine Biosciences Announces Elagolix Scientific Presentations at the 67th Annual Meeting of the American Society for Reproductive Medicine
10. Valeant Pharmaceuticals Intends to Raise Offer for Afexa Life Sciences Inc. to $0.85 per Share
11. Sangamo BioSciences Announces Presentation at the Sixth Annual JMP Securities Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... 2016 France , Germany ... UK, and Israel ). It includes a 10-year epidemiology ... GD, segmented by age and sex in these markets. GD epidemiology report ... is in-depth, high quality, transparent and market-driven, providing expert analysis of disease ... Germany , Italy , Spain ...
(Date:2/4/2016)... LONDON , Feb. 4, 2016 ... to achieve significant growth as next generation systems ... and use radiology for cancer surgery. New systems ... radiological overdosing that has been such a problem ... be delivered. Radiosurgery robots take cancer surgery far ...
(Date:2/4/2016)... , Feb. 4, 2016 Summary ... common cancer and the most common cancer in women ... the disease exceedingly prevalent. The number of women diagnosed ... decades, but the number of deaths has declined due ... cancer treatment has been revolutionized in the past four ...
Breaking Medicine Technology:
(Date:2/5/2016)... ... February 05, 2016 , ... Francisco Canales, MD and Heather ... Napa Valley office. The technique utilizes the body’s own healing abilities to quickly ... Furnas, are part of only a select few cosmetic surgeons bringing this procedure ...
(Date:2/5/2016)... , ... February 05, 2016 , ... ... devoted exclusively to funding innovative lymphoma research and serving the lymphoma community through ... poised to once again host, Swirl, A Wine Tasting Event at the La ...
(Date:2/5/2016)... York (PRWEB) , ... February 05, 2016 , ... Regular ... and find themselves having to wait longer to access the treadmills. It’s a predictable ... Year’s resolutions to lose weight and get in shape by joining gyms, starting new ...
(Date:2/5/2016)... New York, New York (PRWEB) , ... February 05, 2016 , ... ... (APDA) announced the election of Patrick McDermott as Chairman of the National Board of ... welcome Pat as Chairman of the Board,” stated Leslie A. Chambers , APDA ...
(Date:2/5/2016)... ... ... Colorize is a web theme package created exclusively for Final ... dynamic moving camera. Colorize is perfect for personal and web related videos and its ... to 5 focus points per scene, stage floor scene presets that are great for ...
Breaking Medicine News(10 mins):